T he incidence of type 1 diabetes, the immune-mediated form of diabetes, has doubled in each of the past two decades (1) . A large number of immune therapies are being studied to stop or slow the autoimmune destruction of insulin-producing b cells, although none has yet emerged as clinically beneficial. Biostructural data for the related "diabetogenic" alleles, HLA-DQ8 in humans and I-A g7 in the NOD mouse, are now available, allowing structure-guided studies of Ag presentation to T cells (2) . Distinct structural pockets (p1, p4, p6, and p9) that accommodate peptide side chains exist along the peptide binding groove of these class II MHC molecules (3, 4) . An insulin B chain peptide consisting of amino acids 9-23 (B:9-23) is a primary autoantigenic target in the NOD mouse (5, 6) , with the peptide reported to be bound in a low-affinity register (7) . CD4 + T cells with a conserved germlineencoded TCR Va sequence (TRAV5D-4) predominate in the recognition of the insulin B:9-23/I-A g7 complex (8, 9) . This same peptide can also be presented by the DQ8 allele to human TCRs.
Determination of the structural basis for autoantigen recognition in the context of I-A g7 and DQ8 is a key advance in the complex etiology of autoimmune diabetes, but the question remains how to best modulate TCR interactions to prevent or delay disease (10, 11) . In this study, we pursued a rapid and economical smallmolecule drug discovery strategy to modify T cell responses to the autoantigenic B:9-23 peptide. With available crystal structures for the anti-insulin trimolecular complex (MHC-peptide-TCR) in the NOD mouse (3, 11) , we used an in silico molecular docking algorithm to identify small molecules (m.w. ,500) capable of occupying the pockets along the I-A g7 binding groove. We assessed the stimulatory and inhibitory properties of the top-scoring small molecules on T cell responses of both murine and human cells.
Materials and Methods

Molecular modeling and docking
We used crystal structures of I-A g7 complexed to the GAD65 peptide, Protein Data Bank code 1ES0, and HLA-DQ8 complexed to insulin B:9-23, Protein Data Bank code 1JK8, as the basis for molecular docking (12) . An atomic model of I-A g7 complexed to insulin B:9-23 was generated by superimposing the Ag binding cleft of HLA-DQ8 on I-A g7 and applying the same rotation and translation to coordinates for the B:9-23 peptide. To prepare the site for docking, all water molecules were removed and protonation of I-A g7 residues was done with SYBYL (Tripos) (13) . The molecular surface of the structure was explored using sets of spheres to describe potential binding pockets. The sites selected for molecular docking were defined using the SPHGEN program (generates a grid of points that reflect the shape of the selected site) and filtered through CLUSTER. The CLUSTER program groups the selected spheres to define the points that are used by DOCK v5.1.0 (14) to match potential ligand atoms with spheres. Intermolecular AMBER energy scoring (van der Waals + columbic), contact scoring, and bump filtering were implemented in the DOCK program algorithm. Atomic coordinates for ∼140,000 small molecules in the National Cancer Institute Developmental Therapeutics Program (NCI/DTP repository) were positioned in the selected structural pocket in 1000 different orientations and scored based on predicted polar (H bond) and nonpolar (van der Waals) interactions. The best orientation and scores (contact and electrostatic) were calculated. PYMOL was used to generate molecular graphic images.
Generation of insulin B:9-23-specific T cell hybridomas
Creation of BDC 12-4.1 and BDC 12-4.4 T cell hybridomas was previously reported (9) . The BDC 8-1.1 a 1 cell line was produced from splenocytes of a retrogenic mouse with a single 8-1.1 TCR following the same procedure. The 4-8 TCR sequence came from the pancreatic islets of an a-chain-only retrogenic mouse (using the a-chain of BDC 12-4.1).
TCR stimulation LacZ assay
Ag-specific hybridoma stimulation was estimated by measuring LacZ activity. Small molecules for screening were dissolved in DMSO and diluted in PBS for a final concentration of 0.1% DMSO in each well. Each small molecule was screened at a concentration of 100 mM. After small-molecule screening, glyphosine and derivatives were purchased from Sigma-Aldrich and dissolved in PBS, with the pH adjusted to 7.4 for use in the stimulation and ELISPOT assays. Peptides (Genemed Synthesis) for stimulation were HPLC purified (.95%) and dissolved in sterile LPS-free PBS at a neutral pH. Insulin B:9-23 (SHLVEALYLVCGERG) peptide was used at a concentration of 100 mg/ml and the BDC 2.5 mimotope (EKAHRPI-WARMDAKK) at 20 mg/ml. Anti-I-A g7 mAbs (BD Biosciences, catalog no. 554926) were used at a concentration of 10 mg/ml.
Generation of hybridomas expressing a TCR
The 4-8 and human TCR constructs, a-and b-chains linked by the PTV1.2A sequence, were cloned into murine stem cell virus-based retroviral vectors carrying GFP (pMIGII) (15) . Phoenix cells were cotransfected with the pMIGII plasmids and with the pCL-Eco packaging vector, using Lipofectamine 2000 (Invitrogen) to produce replication-incompetent retroviruses encoding TCR sequences. The 5KCa-b-hybridoma line lacking TCR a2 and b-chains was used to reconstitute TCRs (16) . The transduced 5KC hybridomas were sorted by GFP expression, and TCR expression was confirmed by staining with anti-mouse TCRb Ab (clone H57-597; BD Biosciences). 
IL-2 ELISA
Binding analysis
Binding assays performed as previously described exempt use of a biotinstreptavidin-europium detection method (3) . A total of 1.0 mg purified I-A g7 /B:12-23 protein complex was incubated with 0.1 U thrombin (Novagen) to cleave the peptide and linker and 10 uM biotinylated peptides (B:9-23, HEL11-25, and Ea52-68 from Genemed Synthesis) in binding buffer (20 mM HEPES and 150 mM NaCl, pH 7.4), to a total volume of 30 ml overnight at room temperature. Biotinylated peptide-I-A g7 complexes were purified from free peptide using gel filtration Bio-Spin columns (Bio-Rad). A 96-well-high binding plate was coated with 10 mg/ml of an I-A g7 mAb (BD 554926) in 100 mM Na 2 CO 3 , pH 9.6, overnight at 4˚C. Plates were washed with PBS and PBS containing Tween-20; then samples were transferred to the Ab-coated plate and incubated for 4 h at room temperature. Plates were developed with streptavidin-europium and read on a fluorimeter.
Murine ELISPOT assay
IL-10 and IFN-g ELISPOT kits (BD Biosciences) were used for splenocyte analysis. Glyphosine was used at a final concentration of 500 nM for in vitro culture with splenocytes (7 3 10 5 cells per well) and peptide (100 mg/ml). Plates were developed using the AEC substrate system (BD Biosciences), and spots were enumerated using the ImmunoSpot reader and software version 3.1 (Cellular Technology).
Animals
Mice were bred and housed under specific pathogen-free conditions at the University of Colorado Denver Center for Comparative Medicine with an approved protocol from the University of Colorado Denver Animal Care and Use Committee. Spleens for TCR stimulation LacZ assays and ELISPOT assays were obtained from the Barbara Davis Center-derived NOD mouse colony. DQ8 splenocytes were obtained from DQ8/human CD4/I-Ag7null/Rag KO NOD mice from The Jackson Laboratory. BALB/c, C57BL/6, and C57BL/6 congenic for I-A g7 mice were also obtained from The Jackson Laboratory for ELISPOT assays, as were NOD mice for the diabetes prevention study.
Assessment of diabetes
Glucose was measured weekly with the ReliOn blood glucose monitoring system (Solartek), and mice were considered diabetic after two consecutive blood glucose values of .250 mg/dl.
Glyphosine administration
Glyphosine was purchased from Sigma-Aldrich (catalog no. 15149), dissolved in PBS, and injected into the peritoneal cavity. A dose of 80 mg/kg/d was administered in a final volume of 200 ml on 5 d consecutively. Control mice received 200 ml PBS.
HLA genotyping
Informed consent was obtained after the nature and possible consequences were explained to individuals providing serum samples for HLA genotyping and cytokine ELISPOT assay with an approved protocol from the Colorado Institutional Review Board. DRB1 and DQB1 genotyping was performed on patient samples, using linear arrays of immobilized sequence-specific oligonucleotides, similar to previously described methodology (17) .
Human indirect ELISPOT assay
Indirect ELISPOT analyses were conducted as previously described (18), using the human INF-g and IL-10 ELISPOT kits (U-CyTech Biosciences, Utrecht, The Netherlands). Briefly, freshly isolated PBMCs (1 3 10 6 ) were cultured in 250 ml RPMI 1640 containing 10% heat-inactivated human AB serum (PAA Laboratories, Dartmouth, MA) and 10 mM peptide. The cells were fed an additional 250 ml medium after 24 h, and harvested 24 h later. After washing, the cells were resuspended in 300 ml FIGURE 2. Small-molecule inhibitors block presentation of endogenously processed insulin by NOD splenocytes. Inhibition curves for p1 molecules (A) and p6 molecules (B). Dotted line represents IL-2 production by the 4-8 TCR to insulin in the absence of a small molecule. C, IL-2 production from a T cell hybridoma cultured with whole islets used as APCs. The p6:4 molecule inhibits IL-2 production when islets isolated from an adult NOD mouse without diabetes are used for Ag presentation to the 4-8 TCR. *p = 0.004, **p = 0.002, ***p , 0.001. D, p6:4 inhibits B:9-23 peptide binding to I-A g7 , as determined using a soluble binding assay with purified I-A g7 protein and biotinylated insulin B:9-23 peptide. Negative control is uncut I-A g7 (thrombin was not used to cleave the flexible linker and linked peptide), with biotinylated B:9-23 peptide added to the assay. *p = 0.023, **p , 0.001. E, p6:4 inhibits a human DQ8-restricted TCR to insulin B:9-23. *p = 0.004, **p , 0.001. TT, tetanus toxin (negative control peptide). medium and transferred as three 100-ml aliquots to 96-well clear polystyrene culture plates coated with the appropriate cytokine capture mAb and subsequently treated with 1 3 blocking solution (U-CyTech). At 17 h later, the cells were removed by decanting, and the wells were washed (23 with PBS and 53 with PBS containing 0.05% Tween-20). Spots were then formed by sequential incubations with the biotinylated second site anti-IFN-g or anti-IL-10, gold-labeled goat anti-biotin, and a precipitating silver substrate. Spots were enumerated with a Bioreader 4000 Pro X (BIOSYS, Karben, Germany). No Ag wells contained DMSO, as peptides are dissolved in DMSO for the assays. Positive control samples from incubations with tetanus toxin were included in each assay.
Statistical analysis
IL-2 concentrations for T cell stimulation assays, europium counts for protein binding, stimulation indices for glyphosine, and mean spot numbers from ELISPOT assays were analyzed with an unpaired Student t test. Survival curves for the diabetes prevention study were analyzed with the log-rank test. Wilcoxon matched pairs test compared means between groups in the human cytokine ELISPOT assays. Linear regression analysis was done to compare IL-10 ELISPOT assays with B:9-23 6 glyphosine for type 1 diabetic individuals and controls. Statistical tests used GraphPad Prism 4.0 software.
Results
Molecular docking and virtual screening of a small-molecule library
To identify candidate molecules predicted to bind specific structural pockets of the I-A g7 Ag binding groove, we used a supercomputer to screen ∼140,000 small molecules from the NCI/DTP repository of druglike compounds. Existing crystal structures available for modeling include I-A g7 with a bound GAD65 peptide (19) , as well as B:9-23 bound to DQ8 (20) . To model the binding of B:9-23 to I-A g7 , we superimposed the Ag binding clefts of DQ8 and I-A g7 , determined sites of critical contacts between peptide and MHC, and displayed the atomic coordinates of B:9-23 peptide from the solved crystal structure with coordinates of I-A g7 for the solved crystal structure. The identified orientation and conformation of the insulin B:9-23 peptide was complementary with the Ag binding cleft for the crystal structure of I-A g7 (Supplemental Fig. 1 ). All NCI organic compounds were docked in 1000 orientations, using the DOCK program algorithm (14) , and scored based on the sum of attractive and repulsive polar and nonpolar interactions to compute free energy (DG) of binding. Supplemental Table I lists the top 40 scoring compounds for each pocket along with the corresponding NCI identifier.
In vitro screening of lead candidate small molecules
The top 40 scoring compounds for each pocket were screened for their ability to alter anti-B:9-23 T cell responses for different T cell hybridomas (BDC 8-1.1a 1 , BDC 12-4.1, and BDC 12-4.4) (Supplemental Fig. 2 ). The in vitro T cell stimulation assays used hybridomas engineered to produce b-galactosidase following TCR Ag activation (NF of activated T cell promoter) (21) . Upon stimulation, LacZ production correlates with IL-2 production. From the top-scoring 40 compounds predicted to occupy each p1 and p6, a subset resulted in inhibition of B:9-23 TCR activation: 2 of 40 for p1 and 3 of 40 for p6 (Fig. 1A) . In contrast, multiple compounds predicted to bind p9 (20 of 40) resulted in an enhancement of hybridoma responsiveness (p , 0.001, p9 compounds versus pocket 1 and 6, using a rank sum test). Pocket 4 small molecules did not dramatically alter T cell responses to the B:9-23 peptide.
Small molecules inhibit insulin presentation
Five compounds ( Fig. 1A ; Supplemental Table II) inhibited the response of multiple anti-B:9-23 TCRs to varying degrees, with IC 50 values in the low micromolar range. The inhibition curves for the compounds from stimulation assays in the presence of B:9-23 peptide are shown in Fig. 1B-F . Next, we tested the ability of the small molecules to block endogenous insulin presentation. Incubation of whole insulin with I-A g7 -containing splenocytes activates 5KC cells (T cell hybridoma lacking endogenous TCRa2 and b-chains) transduced with a 4-8 TCR. The small molecules examined were able to block T cell stimulation from endogenously processed insulin, with the small molecules p1:17 (pocket 1: compound 17), p6:4, and p6:18 having IC 50 values in low nanomolar concentrations ( Fig. 2A, 2B ). The p6:4 molecule, tetraazatricyclododecane, was studied in additional detail owing to lower IC 50 values and was able to inhibit TCR response to isolated whole islets from an adult nondiabetic NOD mouse (Fig. 2C) , which have been shown to contain dendritic cells with insulin peptides, notably B:9-23 (22) . To document direct effects of these small molecules on inhibiting peptide binding to I-A g7 , we expressed an I-A g7 protein construct in baculovirus with a linked peptide (23) . The flexible linker contained a thrombin cleavage site, allowing for thrombin cleavage of the linker and release of the peptide. In a soluble binding assay, the p6:4 molecule was able to inhibit B:9-23 peptide binding to the empty I-A g7 in a dosedependent manner (Fig. 2D) . We further investigated the binding No stimulation or inhibition inhibition with higher affinity Ags for I-A g7 , HEL11-25, and Ea52-68. We found p6:4 was able to inhibit binding of these biotinylated peptides to a similar degree as the B:9-23 peptide (data not shown).
To test whether these inhibitory small molecules decrease TCR reactivity selectively to B:9-23 insulin peptides, we studied a chromogranin peptide mimotope presented by I-A g7 to the BDC 2.5 T cell hybridoma (24) . Two of the five compounds tested, p1:6 and p6:17, showed no inhibition of chromogranin presentation to the BDC 2.5 hybridoma (Fig. 1B-F) , whereas the other three compounds inhibited both B:9-23 and chromogranin presentation to their respective hybridomas. Other compounds predicted to bind pocket 1 and 6 blocked TCR responses, but not all of these molecules were specific for the B:9-23 peptide. Taken together, these data demonstrate that in vitro small molecules are able to inhibit endogenous insulin presentation and displace B:9-23 peptide binding to I-A g7 , and certain small molecules have specificity for inhibiting insulin presentation to T cells.
Significant homology exists between the high-risk class II allele DQ8 of humans (DQA1*0301-DQB1*0302) and I-A g7 of the mouse (25) . Furthermore, the amino acid sequences of the murine insulin 2 B:9-23 is identical to human B:9-23. We performed in silico molecular docking, using the compounds from the NCI/DTP repository for pockets along the binding groove of DQ8. Twenty of the top 40 scoring compounds for both pocket 6 of I-A g7 and DQ8 are identical, suggesting that small molecules targeted to I-A g7 may similarly bind to DQ8 (for p1, 0 of 40; p4, 5 of 40; and p9, 6 of 40 are identical). We evaluated the p6:4 molecule for the ability to block B:9-23 peptide presentation by DQ8. Using a TCR sequence obtained from a T cell line generated from the peripheral blood of a diabetic individual with the DQ8 molecule, we identified a TCR that is DQ8 restricted and responds to the insulin B:9-23 peptide (26) . Using this TCR along with DQ8 splenocytes from a humanized mouse, we show the p6:4 molecule inhibits TCR activation (Fig. 2E) , suggesting that small molecules targeted to pocket 6 of I-A g7 also bind in a manner similar to that of the human homolog DQ8.
Glyphosine, a pocket 9 compound, enhances T cell responses to insulin B: [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] We hypothesized that small molecules binding to the I-A g7 binding groove would inhibit Ag presentation and subsequent T cell stimulation; however, compounds predicted to bind pocket 9 proved to be stimulatory. Twenty of the 40 top scoring compounds enhanced T cell stimulation of at least one of our three anti-B:9-23 hybridomas in the presence of insulin B:9-23 peptide. One compound, p9:12 (pocket 9: compound 12) glyphosine, enhanced TCR stimulation to B:9-23 when tested with all three of our anti-B:9-23 hybridomas, prompting further evaluation of this compound. To assess specificity of the hybridoma response to glyphosine, the same assays evaluating hybridoma response were performed using 40 "random" compounds from the NCI/DTP repository. Testing of these control compounds did not enhance stimulation above insulin B:9-23 peptide in any of the three hybridomas (p , 0.001, for p9 compounds compared with control compounds, using a rank sum test).
Glyphosine, depicted in Fig. 1A as p9:12, modulated TCR stimulation only when peptide was present (Fig. 3A ). An effect was seen down to a 10 nM concentration, along with an EC 50 concentration of 70.6 nM. The maximal stimulatory effect was at a concentration of 500 nM, which produced an ∼2.5-fold greater stimulation than peptide alone. The enhanced glyphosine response was completely blocked by a mAb against I-A g7 (Fig. 3B) . To test whether glyphosine enhances TCR reactivity specifically to the B:9-23 peptide, we used the BDC 2.5 TCR hybridoma that recognizes a chromogranin peptide presented by I-A g7 . Glyphosine did not enhance peptide stimulation of this hybridoma (Fig. 3C) . We also examined the specificity of glyphosine for I-A g7 by using splenocytes from BALB/c mice, which express I-A d , to stimulate the OVA-specific hybridoma DO11.10. I-A d is structurally similar to I-A g7 of the NOD, with both having identical I-A a-chains but different b-chains (17 aa differences in the I-A b-chains), including b57Asp for I-A d , which results in a structurally distinct pocket 9 compared with b57Ser in the NOD mouse. We found that glyphosine did not stimulate or inhibit the DO11.10 hybridoma (Fig. 3D) .
Next, we evaluated the structure-activity relationship of glyphosine, using compounds we could commercially obtain (Table I) . Derivative 1, with the removal of a CH 2 COOH moiety, did not stimulate or inhibit hybridoma peptide response. Of note, derivative 2, with the substitution of a carboxylic acid for a phosphate group, was able to stimulate both the anti-B:9-23 hybridomas and the BDC 2.5 hybridoma targeting a chromogranin peptide, whereas glyphosine itself stimulated only B:9-23-responsive hybridomas.
Glyphosine stimulates IL-10 production from NOD splenocytes
We next evaluated the in vitro response of a polyclonal T cell population targeted to the B:9-23 peptide (rather than hybridomas). Fig. 4A shows an ELISPOT assay with NOD mouse splenocytes in culture with glyphosine. We found a 3-to 4-fold increase in IL-10, producing cells from NOD splenocytes stimulated with glyphosine plus B:9-23 peptide compared with B:9-23 peptide alone (Fig. 4D,  left columns) . To evaluate the in vivo IL-10 response to glyphosine treatment, adult female NOD mice received daily injections of glyphosine for 5 d. In vivo glyphosine treatment enhanced IL-10 ELISPOT response of ex vivo splenocytes cultured in the presence of B:9-23 peptide (Fig. 4B ), but resulted in no change in IFN-g spots (Fig. 4C) .
To evaluate the strain specificity of glyphosine plus insulin B:9-23 stimulation, ELISPOT assays were performed using age-and sex-matched BALB/c and C57BL/6 mice that have different class II presenting molecules compared with those of NOD mice. BALB/c possess MHC class II I-A d and I-E d . In both BALB/c and C57BL/6 mice, pocket 9 does not have a basic charge, as is the case in NOD mice. Splenocytes from both strains failed to respond to glyphosine plus B:9-23 peptide (Fig. 4D , middle columns), which is not unexpected, as these strains are not prone to develop anti-B:9-23 T cell responses. To test whether this lack of response maps to the MHC, splenocytes from C57BL/6 mice congenic for I-A g7 were cultured with B:9-23 peptide and glyphosine (Fig. 4D, right columns) . The I-A g7 congenic splenocytes responded to glyphosine stimulation in the presence of B:9-23 peptide, genetically mapping the IL-10 response to the MHC region.
Glyphosine treatment delays diabetes onset in NOD mice
IL-10 has anti-inflammatory properties reported to downregulate Th1 cytokines, such as IFN-g (27) , and is associated with Tr1 regulatory T cells (28, 29) . Glyphosine could be an immunomodulatory agent for the treatment and prevention of type 1 diabetes. We evaluated whether in vivo administration would delay the development of diabetes (Fig. 4E) . NOD mice received glyphosine starting at 4 wk of age, with treatment concluded at 21 wk of age. Prevention of diabetes occurred as long as therapy was administered (p , 0.001); however, cessation of glyphosine treatment resulted in diabetes development at a rate similar to that in control mice between 10 and 30 wk of age.
Glyphosine enhances IL-10 ELISPOT assays in HLA-DQ8 type 1 diabetic individuals
With the remarkable homology between murine I-A g7 and human DQ8, we evaluated the glyphosine IL-10 response in human cells, using an indirect ELISPOT assay (30) from DQ8 individuals with and without type 1 diabetes; clinical characteristics and DR genotyping are depicted in Table II . PBMCs were isolated from DQ8 individuals and cultured with peptides (including insulin B:9-23) and glyphosine. The PBMCs were washed, resuspended in media, and then IL-10 and IFN-g spots were developed and enumerated. In type 1 diabetic individuals, IL-10 ELISPOTs were increased with glyphosine and B:9-23 peptide, compared with B:9-23 peptide alone or glyphosine alone (Fig. 5A) . IFN-g ELISPOTs were unchanged with the addition of glyphosine and B:9-23 peptide (Fig. 5B) . DQ8 controls without diabetes did not show any difference in ELISPOT number for IL-10 ( Fig. 5C ) and IFN-g (Fig. 5D ) with the addition of glyphosine. Glyphosine did not alter the IL-10 or IFN-g response to tetanus toxin in type 1 patients with diabetes or controls. In summary, a correlation exists between the number of IL-10 spots with B:9-23 peptide and glyphosine, compared with B:9-23 peptide alone in the diabetic group (Fig. 6A) ; however, no correlation exists in the DQ8 controls without diabetes (Fig. 6B) . 
Discussion
Our studies indicate that small organic molecules identified by an in silico docking algorithm targeted to pockets in the binding groove of the NOD MHC class II molecule, I-A g7 , can alter presentation of the insulin peptide B:9-23. Furthermore, these molecules have similar effects with human components of the anti-insulin trimolecular complex. Pocket 9 compounds resulted in enhanced TCR response, whereas compounds predicted to occupy p1 and p6 inhibited TCR activation.
Small molecules have been used in the context of MHC class II Ag presentation. Molecules exist that act as a catalyst and facilitate peptide loading onto human DR (31, 32) , and a recent study by Call and colleagues (33) identified a small molecule with in vivo activity that accelerated the rate of peptide loading onto DR. Although small molecules have been studied in the context of MHC class II Ag presentation, to our knowledge, our study is the first to identify small molecules, using a molecular docking algorithm, that are predicted to interact with the MHC class II peptide binding groove for the purpose of inhibiting or enhancing the T cell response to a specific target peptide.
Only two small molecules predicted to bind pocket 1 and 6 specifically blocked the T cell response to insulin B:9-23. The insulin B:9-23 peptide can bind to I-A g7 in multiple different registers (34, 35) , and in particular the BDC 12-4.1 hybridoma and other TCRs recognize the B:12-23 peptide in a low-affinity register, termed "register 3." Given the very low affinity register for B:9-23, and the fact that peptide binding is recognized by multiple autoreactive TCRs, the potential exists that small molecules differentially inhibit TCR responses to specific peptides. This potential may explain why specific small molecules inhibit B:9-23 responses, but not the antichromogranin mimotope BDC 2.5 responses, which have a higher affinity for I-A g7 . Unlike the pocket 1 and 6 small molecules, the pocket 9 molecule, glyphosine, enhanced the T cell response to the insulin B:9-23 peptide. The low-affinity register of binding for the B:9-23 peptide presumably has the arginine residue of the peptide occupying pocket 9 along the I-A g7 binding groove (7) . A polymorphism in the gene encoding the b-chain of I-A g7 and DQ8 alters the electrostatic nature of pocket 9 owing to the substitution of serine or alanine for aspartic acid at the b57 position (3, 36) . This substitution disrupts a salt bridge between b57 aspartic acid and a76 arginine, thus allowing the basic arginine residue to interact with the amino acid side chain of peptides bound in p9 of I-A g7 and DQ8 (Supplemental Fig. 1 ). Glyphosine is capable of being negatively charged at a neutral pH, and we postulate that glyphosine changes the register of peptide binding when occupying pocket 9. It has been shown that the peptide amino acid occupied in pocket 9 of I-A g7 , either neutral or negatively charged, can affect TCR/peptide-MHC affinity (4). The enhanced IL-10 response we observed in the presence of glyphosine may reflect this altered TCR interaction.
Glyphosine administration to NOD mice increased IL-10 production from splenocytes (Fig. 4B) without changing IFN-g responses by ELISPOT. With glyphosine, the increased IL-10 spot numbers were more pronounced in the presence of insulin B:9-23 peptide, but this increase was also observed in our no Ag and tetanus toxin controls (∼2-fold higher in the presence of glyphosine). We hypothesize the increased IL-10 response in the presence of glyphosine may be due to insulin peptide-MHC complexes that are already present in the spleens of adult NOD mice or effects on additional endogenous peptides.
In vivo, glyphosine prevention of diabetes was not sustained upon glyphosine withdrawal, and we hypothesize that enhanced IL-10 production following glyphosine treatment contributed to protection from diabetes. IL-10 has anti-inflammatory properties reported to downregulate Th1 cytokines, and may upregulate regulatory T cell responses, such as Tr1 regulatory T cells (27) (28) (29) . Adeno-associated virus vector expression of IL-10 has successfully prevented diabetes when administered to 4-wk-old NOD mice, along with increasing the CD4 + CD25 + regulatory T cell population (37, 38) . This IL-10 hypothesis will require further testing with NOD IL-10 knockout mice or with the use of Abs to IL-10 or the IL-10R; alternatively, the IL-10 response may correlate with other aspects of immunomodulation, which affords protection from diabetes.
In conclusion, our findings demonstrate that a structure-based strategy can pinpoint structural features at the peptide/MHC interface and identify molecules that enhance or inhibit TCR signaling in response to specific peptide Ags. We believe the combination of structure-guided virtual screening and the concept that small molecules targeted to specific MHC pockets can be immunomodulatory has broad relevance to adaptive immunity and autoimmunity.
